

## **Huadong and SCOZIA PHARMA Announce Strategic Collaboration to Develop, Manufacture and Commercialize SCO-094 in Asia Pacific**

- Huadong Medicine is granted from SCOZIA PHARMA an exclusive right to develop, manufacture and commercialize SCO-094 in Asia Pacific region for diabetes, obesity and other metabolic diseases; SCOZIA PHARMA to receive 4 million USD upfront and up to 24 million USD potential regulatory, development and commercial milestone payments. -

Kanagawa, Japan, June 1, 2021 – Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd.(SZ.000963), and SCOZIA PHARMA, Inc, a Japanese biotech company dedicated to developing medicines for lifestyle-related diseases, today announced that the companies have entered into a strategic collaboration to develop, manufacture and commercialize SCO-094, a GLP-1R and GIPR dual agonist treating diabetes, obesity and other metabolic diseases, in 25 countries in Asia Pacific region, including China, South Korea, and Australia, except Japan.

Huadong Medicine has been continuously strengthening its presence and innovative pipeline in metabolism, oncology and immunology areas. This collaboration adds another exciting and new-mechanism asset in Huadong’s metabolism portfolio. It also provides SCOZIA PHARMA access to the second largest pharmaceutical market in the world via Huadong’s development, regulatory, and commercial capabilities. SCOZIA PHARMA is conducting Phase 1 trial of SCO-094 in UK. Huadong Medicine plans to initiate clinical trials in China, leveraging SCO-094 UK trial results.

“SCOZIA PHARMA is a well-regarded biopharmaceutical company in Japan focusing on research and development of cardiovascular, metabolic and renal diseases. This collaboration again demonstrates Huadong’s commitment on R&D transformation and commitment in metabolism area.” stated Liang Lu, Chairman of Huadong Medicine. “SCO-094 is a GLP-1R/GIPR dual agonist, and potentially more efficacious than GLP-1 products on the market. It may become a novel treatment option for diabetes, obesity, NASH and other metabolic diseases.”

“With their long history and successful achievement of developing and commercializing new products in metabolic disease area and strong presence in Greater China, Huadong will be an excellent partner for SCO-094 in Asia Pacific region.” added Yoichi Okumura, President and CEO of SCOZIA PHARMA. “SCO-094 has a unique profile and we are confident that the launch of SCO-094 will provide a new therapeutic option for patients with type 2 diabetes, obesity, NASH and other metabolic diseases ”

Under the terms of the agreement, SCOZIA PHARMA will receive an upfront payment of USD 4 million, and additional milestone payments up to USD 24 million if certain regulatory, development and sales milestones are achieved. SCOZIA PHARMA is also eligible to receive tierd royalties as a percentage net sales of SCO-094 generated in the collaboration territory.

Huadong will be primarily responsible for development, manufacturing and commercialization of SCO-094 in the collaboration territory with the oversight of a joint steering committee comprised

of individuals from both companies. SCOHIA PHARMA will continue to be responsible for the development, manufacturing and commercialization of SCO-094 in Japan and other geographies.

**About SCO-094:**

SCO-094 is a GLP-1R/GIPR dual agonist that leads to HbA1c and body weight reductions by selectively stimulating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Strong receptor binding and ex-vivo activities have been shown in preclinical studies. In animal model, it demonstrates potent efficacy of HbA1c reduction, liver function improvement, triglyceride reduction and liver fat inhibition. Preclinical data support its clinical studies of diabetes, obesity, NASH and other metabolic indications. SCO-094 is currently in Phase 1 study in UK.

**About Huadong Medicine:**

Huadong Medicine Co., Ltd. (SZ.000963) is a leading Chinese pharmaceutical company based in Hangzhou, China. Founded in 1993, Huadong Medicine has fully integrated R&D, manufacturing, distribution, sales and marketing capabilities. Huadong Medicine's product portfolio and pipeline are specialized in oncology, immunology, nephrology and diabetes. The Company's annual revenue in 2020 exceeded 5 billion USD. Huadong Medicine has 10,000 employees, and one of the most extensive commercial coverage and marketing capabilities in China. 'Patient Centered, Science Driven' is Huadong's value. For additional information, please visit [www.eastchinapharm.com/en](http://www.eastchinapharm.com/en).

**About SCOHIA PHARMA, Inc.:**

SCOHIA PHARMA, Inc. is a drug discovery bioventure focusing on the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases. Our R&D team has a rich pipeline and track record in each stage of drug development, including compound discovery, drug evaluation, and clinical development, which makes us special. For detailed information about SCOHIA PHARMA, Inc., please visit <https://www.scohia.com/eng/>.

**Investor Relations and Media**

**Huadong Medicine:**

Bo Chen

+86 571 8990 3290

[pretor@eastchinapharm.com](mailto:pretor@eastchinapharm.com)

**SCOHIA PHARMA:**

Corporate Communication

[info@scohia.com](mailto:info@scohia.com)